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Abstract
Background and Purpose: Microglia are resident immunocompenent and phagocytic cells of central nervous system (CNS),
which produce various cytokines and growth factors in response to injury and thereby regulate disease pathology. The
purpose of this study is to investigate the effects of microglial transplantation on focal cerebral ischemia model in rat.
Methods: Transient middle cerebral artery occlusion (MCAO) in rats was induced by the intraluminal filament technique.
HMO6 cells, human microglial cell line, were transplanted intravenously at 48 hours after MCAO. Functional tests were
performed and the infarct volume was measured at 7 and 14 days after MCAO. Migration and cell survival of transplanted
microglial cells and host glial reaction in the brain were studied by immunohistochemistry. Gene expression of neurotrophic
factors, cytokines and chemokines in transplanted cells and host rat glial cells was determined by laser capture
microdissection (LCM) and quantitative real time-PCR.
Results: HMO6 human microglial cells transplantion group demonstrated significant functional recovery compared with
control group. At 7 and 14 days after MCAO, infarct volume was significantly reduced in the HMO group. In the HMO6
group, number of apoptotic cells was time-dependently reduced in the infarct core and penumbra. In addition, number of
host rat microglia/macrophages and reactive astrocytes was significantly decreased at 7 and 14 days after MCAO in the
penumbra. Gene expression of various neurotrophic factors (GDNF, BDNF, VEGF and BMP7) and anti-inflammatory cytokines
(IL4 and IL5) was up-regulated in transplanted HMO6 cells of brain tissue compared with those in culture. The expression of
GDNF and VEGF in astrocytes in penumbra was significantly up-regulated in the HMO6 group.
Conclusions: Our results indicate that transplantation of HMO6 human microglial cells reduces ischemic deficits and
apoptotic events in stroke animals. The results were mediated by modulation of gliosis and neuroinflammation, and
neuroprotection provided by neurotrophic factors of endogenous and transplanted cells-origin.
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Introduction
Microglia are immunocompetent cells of central nervous system
(CNS), which are activated in response to injury and diseases, and
adopt a phagocytic and cytokine secreting phenotype [1–4].
Microglia are activated following in cerebral ischemia and express
a variety of proinflammatory cytokines including interleukin -1b
(IL-1b), interleukin -6 (IL-6) and tumor necrosis factor -a (TNF-a),
which induce in neuroinflammation and neurotoxicity [5–8]. It
also take part in neuroinflammation through chemokines, such as
monocyte chemotactic protein-1 (MCP-1) and macrophage
inflammatory protein -1a (MIP -1a), production and recruitment
to circulating immune cells [9–11].
Conversely, microglia is known to produce neurotrophic factors
such as glial cell line-derived neurotrophic factor (GDNF), brain-
derived neurotrophic factor (BDNF), basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor (VEGF), potentially
provide trophic support to neurons in distress [12–14]. These
reports suggest that the phenotypic expression of microglia,
whether it is to be neuroprotective or neurodegenerative, depends
on the cue it receives during a particular disease process.
Regenerative medicine using stem cell-based cell therapy has
recently emerged as a therapeutic tool in various disease settings
[15]. Various cell types including neural stem cells, mesenchymal
stem cells (MSCs) and immortalized stem cell lines have been used
for stem cell based therapy in experimental settings, as well as
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disease pathology. Indeed, several resent reports have implicated
the beneficial effects of cell-transplantation including neural stem
cells, MSCs and genetically engineered stem cell line [16,17].
Since microglia are able to act neuroprotectively in the CNS in
injury or disease, we hypothesized that microglial transplantation
could provide neuroprotection of neurons under cerebral ischemic
condition. Wehave previously generated an immortalized cellline of
human microglia, HMO6, which carries morphologic and pheno-
typic expression characteristic of primary human microglia [18,19].
To test our hypothesis, we intravenously transplanted HMO6
human microglia cells in rat model of transient ischemia, and
evaluated histopathological, molecular and functional recovery in
these ischemia model animals.
Materials and Methods
Cell culture
A human microglial cell line, HMO6, was established by
isolating microglia from human fetal telencephalon tissue and
immortalizing it using a retroviral vector encoding v-myc [19].
HMO6 cells were cultured in medium consisted of Dulbecco’s
modified Eagle medium (DMEM; Nissui, Tokyo, Japan) supple-
mented with 5% fetal bovine serum, L-glutamine, amphotericin B
and gentamicin. After 24, 48, 60 and 72 h of growth, cells were
exposed briefly to trypsin and then collected by centrifugation.
HMO6 cells at final concentration of 3610
6 cells per 100 ml
DMEM were prepared for transplantation.
Middle cerebral artery occlusion (MCAO) model
All experimental protocol and procedures were approved by the
Ethical Committee of the Shimane University School of Medicine.
Adult male Sprague-Dawley rats (n=60; 7–8 weeks old; CLEA
Japan,Tokyo) weighting 250 to 300 g were employed in our
experiments. Briefly, rats initially anesthetized with 4% halothane
and maintained with 1–2% halothane in 70% N2O and 30% O2
mixture using a face mask. Transient MCAO was induced using a
previously described method of intraluminal vascular occlusion
[20]. The right common carotid artery, external carotid artery and
internal carotid artery were exposed via a ventral midline incision.
A 4-0 monofilament nylon suture (Nescosuture, Tokyo, Japan),
with its tip rounded by coated with silicon (Xantopren L blue,
Heraeus Kulzer, Hanau, Germany) was inserted from the right
external carotid artery into of the internal carotid artery to block
the origin of the right middle cerebral artery. At 90 minutes after
MCAO, occluded animals were re-anesthetized with halothane
and nylon monofilament was removed, and the end of the external
carotid artery was tied. The rats were allowed to recovery from
anesthesia and returned to the cages.
Transplantation of HMO6 cells
In the study, MCAO rats were randomly divided into two
experimental groups: Transplantation (n=30) and control (n=30)
groups. Forty eight hour after MCAO animals were anesthetized
and HMO6 cells (3610
6 cells/rat) were injected through jugular
vein. In control MCAO animals, phosphate-buffered saline (PBS)
alone was injected. No immunosuppressant such as cyclosporine A
was utilized in the study as well as previous studies since
cyclosporine A reduces glial response and exerts neuroprotection
in experimental stroke.
Functional tests
Functional tests were performed at 1, 4, 7, 10 and 14 days after
MCAO by the modified neurological severity scores (mNSS).
mNSS was used to grade the various aspects of neurological
functions, which was adopted from a previous report, with some
modification [21]. The modified NSS (mNSS; Table 1) is a
composite of motor (i.e., muscle status and abnormal movement),
sensory (i.e., visual, tactile, and proprioceptive), beam balance, and
reflex tests, in which meticulous sensory examination for vision,
touch, and proprioceptive sensation was performed. The total
score for the test was 22 points. Increasing score indicates the
severity of injury. In a preliminary examination, rats with 12–16
points of mNSS had a stable stroke volume. Hence, we used rats
with 12–16 points for further examination.
Triphenyltetrazolium chloride (TTC) staining and
evaluation of infarct volume
Rats (8 rats in each group; n=16) were decapitated under deep
anesthesia with an overdose of diethyl ether at 7 and 14 days after
MCAO. The brain was immediately removed and sectioned into 2
mm thick slices from the frontal pole to the cerebellum. These
Table 1. Modified NSS.
Motor Tests Points
Raising rat by the tail 3
1 Flexion of forelimb
1 Flexion of hindlimb
1 Head moved .10 to vertical axis within 30 s
Placing rat on the floor (normal=0; maximum=3) 3
0 Normal walk
1 Inability to walk straight
2 Circling toward the paretic side
3 Fall down to the paretic side
Sensory tests 6
1 Placing test (visual test)
2 Placing test (tactile test)
3 Proprioceptive test (deep sensation, pushing
the paw against the table edge to stimulate limb
muscles)
Beam balance tests (normal=0; maximum=6) 6
0 Balances with steady posture
1 Grasps side of beam
2 Hugs the beam and one limb falls down from the beam
3 Hugs the beam and two limbs fall down from
the beam, or spins on beam (.60 s)
4 Attempts to balance on the beam but falls off (.40 s)
5 Attempts to balance on the beam but falls off (.20 s)
6 Falls off: No attempt to balance or hang
on to the beam (,20 s)
Reflexes absent and abnormal movements 4
1 Pinna reflex (head shake when touching the auditory meatus)
1 Corneal reflex (eye blink when lightly touching the cornea
with cotton)
1 Startle reflex (motor response to a brief noise from
snapping a clipboard paper)
1 Seizures, myoclonus, myodystony
Maximum points 22
One point is awarded for inability to perform the tasks or for the lack of a tested
reflex.
doi:10.1371/journal.pone.0011746.t001
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saline at 37uC for 30 minutes, after which sections rinsed 0.9%
saline solution for photography. TTC stained sections per animal
were photographed using digital high definition microscope
(Keyence VH-7000, Osaka, Japan). The six areas of infarction
between each adjoining slice were measured using NIH image
software, and then infarct volumes (mm
3) were determined by
integrating the appropriate area with the section interval thickness.
Histological and immunohistochemical assessment
Experimental animals, two groups of 4 each (total n=32) at 3,
5, 7 and 14 days after MCAO, were re-anesthetized and rat organs
were fixed by transcardial perfusion with saline, followed by 4%
paraformaldehyde (PFA) in 0.1mol/L phosphate buffer (PB,
pH 7.4) and 10% sucrose. The rat tissues (brain, liver, spleen,
lung, kidney) were immersed in 20% sucrose for 48 hours and then
were embedded in TissueTek OCT compound and frozen on dry
ice. The brain tissues were cut equally spaced (thickness 2 mm)
coronal blocks, followed by sections sliced into 10 mm in a cryostat.
To investigate the histological changes in the brain tissue,
haematixiine and eosine (H.E.) staining was performed.
For immunostaining, brain sections were incubated with mouse
monoclonal antibody specific to Human nuclei (1:100; MAB1281,
Chemicon, Temecula, CA) to evaluate the migration of trans-
planted HMO6 cells. Double immunohistochemical staining was
performed to identify glial cells accumulation with polyclonal
rabbit anti-GFAP antibody (1:100; Dako, Carpinteria, CA) and
monoclonal mouse anti - ED1 antibody (1:100; Serotec, Oxford,
UK). Sections were then incubated for 1 hour at room
temperature with secondary antibodies, Texas red- conjugated
goat anti-rabbit IgG (1:100,Chemicon) and FITC-conjugated goat
anti-mouse JgG (1:100; Chemicon). All sections were stained with
Hoechst 33258 (10 mg/ml, Sigma) as a nuclei staining. After
staining, sections were mounted with ultramount (Dako) and
visualized or photographed with fluorescence microscopy system
(Nikon, ECLIPSE, E600, Tokyo, Japan). ED1 is specific for
mouse/rat microglia/macrophages and not for human.
The terminal deoxynucleotidyl transferase (TdT) - mediated
dUTP-biotin nick – end labeling (TUNEL) method was used to
assess apoptotic cell death. Brain sections were stained by In Situ
Cell Death Detection Kit (Roche Diagnostics, Mannheim,
Germany). After quenching endogenous peroxidase activity with
0.3% H2 O2 in PBS, slides was placed in TdT. A dark brown color
indicating DNA breaks developed after incubation with 3, 39-
diaminobenzidine (DAB, Vector Lab, Burlingame, CA).
Laser capture microdissection (LCM)
Tissue preparation and staining: The animals, two groups of 6
each (total n=12) at 5 days after MCAO, were deeply
anesthetized, decapitated and the brains were quickly removed.
The brain sections were snap frozen with liquid nitrogen and
stored at 280uC for further use. Ten-mm brain cryosections were
prepared, fixed in 75% ethanol for 30s. For detection of HMO6
cells, sections were incubated with anti- human nuclei, for
detection of rat glial cells, incubated with, anti- GFAP and anti-
ED1 antibody for 1 hour followed by secondary antibody for 30
minutes. During immunostaining, RNase inhibitor was added to
all reagents, and aqueous reagents were prepared in with
diethylpyrocarbonate (DEPC) treated distilled water.
Immunostaining-positive cells for human nuclei, GFAP or
ED1 were respectively isolated from ischemic hemispheres of
MCA occluded rats by LCM system (Arcturus, Mountain View,
CA), which was equipped with an inverted base microscope
system (Olympus, Tokyo, Japan). Microdissections of rat brain
sections were performed under 10x objective and target cells
w e r ec o l l e c t e df r o me a c hr a tb r a i no na nL C MC a p( C a p S u r e
Macro Caps, Arcturus; Mountain View, CA). Following cells
collection, total RNA was isolated with the PicoPure RNA
isolation kit (Arcturus; CA) according to the manufacturer’s
instructions.
Real time PCR
Total RNA of HMO6 cell culture was isolated from confluent
HMO6 using RNA STAT reagent (TELTEST) according to the
manufacturer’s instructions. Briefly, confluent HMO6 cells of 60-
mm cell culture dishes were lysed and extracted with chloroform,
and the aqueous phase was transferred to a fresh tube. Total RNA
was precipitated with 2-propanol, washed once with 70% ethanol,
and re-suspended in a suitable volume of DEPC-treated water.
The total RNA concentration was determined by measuring the
OD values of the samples at 260 nm.
To prepare first strand cDNA, mRNA was reserve transcribed
with reverse transcriptase enzyme (ReverTraAce, Toyobo, Osaka,
Japan) in a total 20 ml reaction mixture. To analyze mRNA level,
real time PCR was performed with SYBR PCR Master Mix
(power SYBR green, Applied Biosystems, CA) and an ABI Prism
7000 Sequence Detector system (Applied Biosystems, CA). The list
of primer sequences is provided in Table 2. After normalization
with GAPDH mRNA, the target gene mRNA level in a sample
was quantified by relative quantification method.
Statistical Analysis
Data were expressed as mean 6 standard error of the mean
(S.E.M). Experimental data were analyzed by analysis of variance
and means with ANOVA followed by Fisher’s PLSD test for the
difference between means. A values of P,0.05 and P,0.01 were
considered statistically significant.
Results
Neurological functional recovery
We investigated whether transplanted human microglial cell,
HMO6 improves neurological deficits after MCAO in rat. The
mNSS scores at 1 and 4 days were not significant different
between control group and HMO6 transplantation group.
However, neurological functional recovery was significantly found
at 7, 10 and 14 days after MCAO in the HMO6 transplantation
group compared with the control group (Figure 1A).
Measurement of Infarct volume and histological changes
Histological analysis of ischemic lesions indicated that at 7 days
after MCAO the mean infarct volume was 163617 mm
3 in the
control group and 91616 mm
3 in the HMO6 transplanted group
(44% reduction in infarct volume), and at 14 days after MCAO
the infarct volume was 214629 mm
3 in the control and 127620
mm
3 in the HMO6 group (41% reduction in infarct volume)
(Figure 1B). There were significant reductions in infarct volumes
following transplantation of HMO6 human microglia in MCAO
animals at 7 and 14 days after MCAO. Tissue damage with
disarrangement and vacuoles and cell infiltration in infarct core
and penumbra were higher in control groups compared to those
in transplanted groups during the time course (Figure 1C and
1D).
Apoptotic cells
Number of apoptotic cells was counted in the ischemic core and
the penumbra at 3, 5, 7 and 14 days after MCAO in brain sections
processed for TUNEL staining. Number of apoptotic cells at 3 and
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(Figure 2J) were not significant different between the HMO6
transplantation group and the control group.
At 7 days after MCAO, the number of apoptotic cells within the
ischemic core was 70.965.9 cells/field in the control group and
30.467.6 cells/field in the HMO6 transplantation group respec-
tively (41% reduction in number of apoptotic cells) (Figure 2E). At
14 days after MCAO, the number of apoptotic cells within the
ischemic core was 45.766.6 in the control (Figure 2F) and
8.261.4 in the HMO6 group respectively (82% reduction in
number of apoptotic cells) (Figure 2H and 2E).
At 7 days after MCAO, the number of apoptotic cells within the
penumbra was 59.167.9 cells/field in the control group and
14.763.1 cells/field in the HMO6 transplantation group respec-
tively (75% reduction in number of apoptotic cells) (Figure 2J). At
14 days after MCAO, the number of apoptotic cells within the
penumbra was 20.962.1 in the control (Figure 2G) and 1.960.4
in the HMO6 group respectively (91% reduction in number of
apoptotic cells) (Figure 2I and 2J).
Migration of HMO6 human microglial cells
At 3, 5, 7 and 14 days after MCAO, migration of HMO6 cells
into brain was examined by human nuclei (HuN) staining. In the
brain, HuN-positive HMO6 cells were found in survive infarct
core and penumbra in the ipsilateral hemisphere, while in the
contralateral hemisphere HMO6 cells were not found. A peak of
HMO6 cell migration was found at 5 days after MCAO (Figure 3A
and 3B) as compared with 3, 7 and 14 days (Figure 3C and 3D).
Migration declined after the 7 day after MCAO and only a small
number of HMO6 cells was detected at 14 days after MCAO
(Figure 3E). HMO6 cells were also transplanted in healthy rats to
find out whether they enter into normal brains. However, HuN-
positive cells were detected only in optic chiasma.
Since HMO6 cells were transplanted intravenously, migration
and localization of HMO6 cells in other parts of body were
determined. The presence of HuN-positive cells was found in the
spleen, lung, liver and kidney at 3, 5, 7 and 14 days. HMO6 cell
migration in the spleen was significantly higher at 5 days (Figure 3F
and 3J) as compared with 7 and 14 days (Figure 3H and 3J).
Table 2. Primers for real time PCR.
Gene Sense Antisense
Gene bank ACC
number
human GDNF TTTAGGTACTGCAGCGGCTCTT TCACTCACCAGCCTTCTATTTCTG NM000514
human BDNF ATTACAATCAGATGGGCCACATG AGGGAGAAAGCAGAAACAAGACA M61176
human b-FGF CGACCCTCACATCAAGCTACA AACGGTTAGCACACACTCCTT NM002006
human VEGF GGCCAGCACATAGGAGAGATG AGGCCCACAGGGATTTTCTT AF022375
human BMP-7 CGTGGAACATGACAAGGAATTC CGTGACAGCTTCCCCTTCTG NM001719
human CNTF TGTGCGTGCTTGCATGTG ACCCTGAAGTGGAAGGACGTT NM000614
human IL-1b TTACAGTGGCAATGAGGATGA TGTAGTGGTGGTCGGAGATT NM000576
human IL-4 AACAGCCTCACAGAGCAGAAGAC GTGTTCTTGGAGGCAGCAAAG NM000589
human IL-5 TGGAGCTGCCTACGTGTATGC GCAGTGCCAAGGTCTCTTTCAC NM000879
human IL-6 CCTGAGAAAGGAGACATGTAACAAGA TGGAAGGTTCAGGTTGTTTTCTG M54894
human IL-8 CTGGCCGTGGCTCTCTTG TTAGCACTCCTTGGCAAAACTG NM000584
human IFN-g GTCCAACGCAAAGCAATACATG CCTTTTTCGCTTCCCTGTTTTAG NM000619
hu Fractalkine CATCACGTGCAGCAAGATGAC CGCATGATGCCTGGTTCTG NM134455
human MCP-1 GACCATTGTGGCCAAGGAGAT TGTCCAGGTGGTCCATGGA NM002982
hum GAPDH CCACATCGCTCAGACACCAT TGACCAGGCGCCCAATA M33197
rat GDNF CTCGAAGTAGAAGGCTAACA AGCGGAATGCTTTCTTAGG NM017017
rat BDNF TGTCCGAGGTGGTAGTACTTCATC CATGCAACCGAAGTATGAAATAACC NM012842
rat b-FGF GAGAGAGGAGTTGTGTCCATCAAG GCAGCCGTCCATCTTCCTT X61697
rat VEGF GAGGAAAGGGAAAGGGTCAAAA CACAGTGAACGCTCCAGGATT AF062644
rat IL-1b CACAGCAGCATCTCGACAAGA CACGGGCAAGACATAGGTAGCT NM31512
rat IL-4 CAGGGTGCTTCGCAAATTTTAC ACCGAGAACCCCAGACTTGTT NM_201270
rat IL-6 TCAACTCCATCTGCCCTTCAG AAGGCAACTGGCTGGAAGTCT M26744
rat IL-10 AGAAGCTGAAGACCCTCTGGATAC GCTCCACTGCCTTGCTTTTATT L02926
rat TNF-a CAGCCGATTTGCCACTTCATA TCCTTAGGGCAAGGGCTCTT X66539
rat TGF-b CGTGGAAATCAATGGGATCAG CAGGAAGGGTCGGTTCATGT NM021578
rat IL-8 GAAGATAGATTGCACCGA CATAGCCTCTCACACATTTC
rat MCP-1 CCAGAAACCAGCCAACTCTCA AAGCGTGACAGAGACCTGCAT NM031530
rat MIP-1a CATTCCTGCCACCTGCAAAT CAAGTGAAGAGTCCCTGGATGTG NM013025
rat iNOS AAGAACTCGGGCATACCTTCAG GTCATGAGCAAAGGCACAGAAC NM012611
rat GAPDH CAGCCTCGTCTCATAGACAAGATG AAGGCAGCCCTGGTAACCA AF106860
doi:10.1371/journal.pone.0011746.t002
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the lung as compared with 7 days and the number of cells was
much lower oncompared with 7 and 14 days (Figure 3J).
Effect of HMO6 transplantation on glial cell accumulation
Effect of HMO6 transplantation on glial reaction in the
ischemic core and the penumbra region was investigated with
ED1 and GFAP immunostaining. ED1-positive cells, representing
host rat microglia/macrophages, were found in the ischemic core
to penumbra of the ipsilateral hemisphere. Number of ED1-
positive cells was smaller in the penumbra as compared with the
ischemic core (Figure 4I and 4J). In the ischemic core, number of
round-shaped ED1 positive cells at 7 and 14 days after MCAO
was significantly decreased in the HMO6 transplantation group
as compared with control group. At 7 days after MCAO, the
number of ED1-positive cells was 90.466.4 cells/field in the
control group (Figure 4A) and 55.261.7 cells/field in the HMO6
transplantation group respectively (39% reduction in number of
apoptotic cells) (Figure 4C). At 14 days after MCAO, the number
of ED1-positive cells was 70.965.9 cells/field in the control
(Figure 4B) and 35.161.9 cells/field in the HMO6 group
respectively (50% reduction in number of apoptotic cells)
(Figure 4D).
In the penumbra at 7 days after MCAO, number of ED1-
positive cells was 68.264.4 cells/field in the control group
(Figure 4K) and 29.164.7 cells/field in the HMO6 transplantation
group respectively (57% reduction in number of ED1 cells)
(Figure 4K). At 14 days after MCAO, the number of ED1-positive
cells was 59.162.5 cells/field in the control (Figure 4K) and
23.761.1 cells/field in the HMO6 group respectively (60%
reduction in number of ED1 cells) (Figure 4K).
At 7 days after MCAO, number of GFAP-positive cells was
84.364.5 cells/field in the control group (Figure 4E and 4L) and
48.261.5 cells/field in the HMO6 transplantation group respec-
tively (43% reduction in number of GFAP cells) (Figure 4G and
4L). At 14 days after MCAO, the number of GFAP-positive cells
was 70.167.1 cells/field in the control (Figure 4F and 4L) and
30.261.7 cells/field in the HMO group respectively (57%
reduction in number of GFAP cells) (Figure 4H and 4L).
Gene expression of neurotrophic factors, cytokines and
chemokines in HMO6 cells in culture and brain tissue
Gene expression of neurotrophic factors, cytokines and
chemokines was determined in HMO6 cells in culture and the
brain by real time-PCR (Figure 5). The results showed that
expression of b-FGF and IL-8 in HMO6 cells were high, while
expression of GDNF, BDNF, CNTF, IL-5, IL-6, IFN-c, fractalk-
ine and MCP-1 was low and expression of VEGF, BMP-7, IL-1b,
IL-4 in HMO6 cells was not detected and under un-stimulated in
vitro culture conditions.
To study the actual gene expression in transplanted HMO6
cells in the brain, HMO6 cells from brain tissue at 5 days after
MCAO were isolated by the use of with LCM and gene expression
of neurotrophic factors, cytokines and chemokines was measured
by real time-PCR. Expressions of GDNF, BDNF, VEGF, BMP-7,
CNTF, IL-1b, IL-4, IL-5, IFN-c, fractalkine and MCP-1 were up-
regulated in HMO6 cells of brain tissue as compared with those in
culture. On the other hand, expressions of b-FGF, IL-6 and IL-8
were down-regulated in HMO6 cells of brain tissue compared
with HMO6 cell culture.
Gene expression of neurotrophic factors, cytokines and
chemokines in rat microglia and astrocytes of brain tissue
To determine the effect of the HMO6 transplantation on host
brain microglia and astrocyte, gene expression of neurotrophic
factors, cytokines and chemokines was investigated in rat glial cells
of the penumbra from brain tissue with the LCM at 5 days after
MCAO by real-time PCR.
There were no significant differences between transplanted
group and control group in expression of neurotrophic factors,
Figure 1. Effect of HMO6 transplantation on neurological
function, infarct volume and tissue damage. (A) Neurological
function of the experimental groups after MCAO was determined by
the modified Neurological Severity Scores (mNSS). The mNSS summa-
rizes the results of motor, sensory, reflex, and balance tests.
Transplantation of HMO6 human microglial cells enhanced neurological
functional recovery at 7, 10 and 14 days after MCAO. (B) Infarct volume
was calculated at 7 and 14 days after MCAO in the HMO6
transplantation and control groups based on TTC staining and NIH
image software. Data of mNSS and infarct volume is expressed as the
mean 6 SEM. *P,0.05, ** P,0.01, as compared with the control group.
H.E. staining of the penumbra lesion in a control rat (C) and a
transplanted rat (D) at 7 days after MCAO. Bar =100 mm.
doi:10.1371/journal.pone.0011746.g001
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(Figure 6A). The expressions of GDNF and VEGF in astrocytes
of penumbra were significantly up-regulated in the transplanta-
tion group as compared with the control group. Expressions of
BDNF, IL-1b, IL-4, IL-6, TNF-a, TGF-b, IL-8, MCP-1 and
MIP-1a were higher in astrocytes of transplanted brain than
those in astrocytes of control brain, though not significantly
different (Figure 6B).
Discussion
The major findings of the present study are that intravenous
transplantation of human microglial cells significantly improved
the ischemia-induced functional and morphological changes in the
ipsilateral hemisphere after t-MCAO.
Previous studies have reported that intravenous transplantation
of neural stem cells (NSCs), MSCs and human umbilical cord
Figure 2. Effect of HMO6 transplantation on apoptosis. TUNEL positive cells were shown in the HMO6 transplantation (C, D, H and I) and
control group (A, B, F and G) at 3 (A-D) and 14 (F-I) days after MCAO. Number of apoptotic cells was determined in the infarct core (E) and the
penumbra (J). Number of apoptotic cells is expressed as the mean 6 SEM. Bar =20 mm, *P,0.05, ** P,0.01, as compared with the control group.
doi:10.1371/journal.pone.0011746.g002
Figure 3. Distribution of human nuclei positive cells after HMO6 cell transplantation. Human nuclei (HuN, FITC) positive cells were
detected by fluorescence microscope at 5 (A and B) and 14 (C and D) days after MCAO in the infarct core (A and C) and the penumbra (B and D) of the
brain. Histogram (E) shows the number of HuN-positive cells in infarct core (empty bars) and penumbra (solid bars), counted at X400 magnification.
HuN-positive cells in internal organs were shown at 5 (F and G) and 7 (H and I) days in the spleen (F and H) and lung (G and I). Histogram (J) shows the
number of HuN-positive cells in spleen, liver, kidney and lung, counted at X400 magnification in the time course after MCAO. Number of HuN-positive
cells is expressed as the mean 6 SEM. Bar =20 mm, * P,0.05 vs. infarct core at 3 and 14 days, ** P,0.01. vs. penumbra at 3, 7 and 14 days.
# P,0.05
vs. spleen at 7 and 14 days,
## P,0.05 vs. lung at 7 and 14 days.
doi:10.1371/journal.pone.0011746.g003
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after experimental stroke [15,17,21,22], which raised the possibil-
ity of cell therapy for ischemic stroke. Most of stem cells/precursor
cells are believed to enter into brain through disrupted blood-brain
barrier and migrate to the ipsilateral hemisphere, especially to the
ischemic border zone expressed as penumbra [15,23], which is
also supported by our data that HMO6 cells transplanted in
healthy rats did not enter the brains except optic chiasma. HMO6
human microglial cells transplanted in MCAO rats also were
found in penumbra, however, the cell density was higher along
infarct core. As expression of cytokines and chemokines are
upregulated in the penumbra, transplanted microglial cells
carrying respective receptors are thought to be chemo-attracted
and recruited and migrate along the infarct core [9,24]. Tissue
damage in the infarct core and penumbra was not induced by
HMO cell transplantation and migration, rather an improvement
of histological tissue architecture was observed. On the contrary,
migrated HMO6 cells almost disappeared from the brain 14 d
after MCAO. Fate of HMO6 cells localized in the lesion should be
determined in the further study.
In the rodent MCAO studies, TUNEL-positive cells in the
ischemic lesion peaked at about one week after MCAO and were
continuously seen for several weeks [25,26]. Previous reports have
indicated that systemically transplanted stem cells reach the
ischemic lesion and have a neuroprotective effect to reduce
apoptotic neuronal cell death in host neurons and that reduction of
stroke volume began after the event. Neuroprotective effect to
reduce the number of apoptotic cells was found at 7days after
MCAO in the present study and then, infarct volume of both PBS
control and HMO transplantation groups continued to increase
up to two weeks as seen in previous studies [27,28]. The reason
remains elusive, but various factors including apoptotic signal
pathway, necrosis and repair process might affect it. Transplan-
tation of bone marrow stromal cells and GDNF-gene modified
NSCs reduced the number of TUNEL-positive cells, caspase-3-
positive cells and also neuronal degeneration from the acute phase
to several months after MCAO [25,29,30], which was consistent
with microglial transplantation in this study.
Brain injury following focal cerebral ischemia triggers activation
of microglia and astrogliosis and induction of released free
Figure 4. ED1 and GFAP positive cells in the penumbra. Immunohistochemical reactions to ED1 (A-D: FITC) and GFAP (E-H: Texas red) were
shown at 7 (A, C, E and G) and 14 (B, D, F and H) days after MCAO. Double staining with anti-ED1 and anti-GFAP antibodies was detected in the
penumbra of the HMO6 transplantation group (J) and control group (I) at 7 days after MCAO. Histograms show the density of ED1-positive microglia/
macrophages (K) and GFAP-positive astrocytes (L) in the HMO6 transplantation and control groups of 7 and 14 days after MCAO. Number of positive
cells is expressed as the mean 6 SEM. Bar =20 mm, ** P,0.01 compared to the control group.
doi:10.1371/journal.pone.0011746.g004
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activated microglia releasing reactive oxygen species, nitric oxide,
chemokines and inflammatory cytokines[35,36] leading to accu-
mulation and activation of more blood born and resident immune
cells. Moreover, these microglial inflammatory products are highly
neurotoxic. The study in cerebral ischemic model demonstrated
that the application of immunosuppressant (FK506) reduced
delayed neuronal death by glial/microglial inhibition [37]. In the
present study, significantly fewer number of host rat ED1-positive
microglia/macrophage was detected in the infarct core and
penumbra in HMO6 human microglia-transplanted brains. It
appears that transplantation of HMO6 human microglia in the
ischemic brain induces reduction in host glial activation that leads
to abated neurotoxicity. In addition, transplanted HMO6 human
microglia showed increase expression of several neurotrophic
factors and Th2 type cytokines, which might be involved in glial
inhibition and also protection of host neurons. In the transplanted
brain, the number of GFAP-positive astrocytes in the penumbra
was lower indicating curtailed astrogliosis in the lesion site.
Recently, it is proposed that astrocytes contribute to delayed
neuronal death by release of cytotoxic cytokines after ischemia
[38,39]. The present results of abated astrogliosis and the
reduction in the number of TUNEL-positive cells in the penumbra
are in good agreement with these studies.
In the HMO6-transplanted group, reduced infarct volume and
reduction in the number of glial cells in penumbra were observed
from 7 days after MCAO and onward. It appears that the
transplanted HMO6 human microglial cells attenuate glial
reaction of host glial cells, which leads to reduce infarct volume,
by increased expression of neurotrophic factors, cytokines and
chemokines. It is interesting to note that several neurotrophic
factors such as GDNF, BDNF, BMP-7, CNTF and VEGF were
upregulated in the transplanted HMO6 human microglial cells as
compared to HMO6 cells in culture. Increased expression of these
trophic factors in transplanted HMO6 cells might have resulted
from inducing signals at the microenvironment of the ischemic
brain. In the present results, anti-inflammatory cytokines such as
IL-4 and IL-5 were also increased although IL-1b, a proin-
flammatory cytokine and MCP-1, a chemokine, were also
increased. These results indicate that the gene expression in the
transplanted HMO6 human microglial cells was dramatically
changed in the microenvironment of ischemic brain lesion site.
Previous reports demonstrated that transplantation of gene-
modified human MSCs overepressing GDNF, BDNF, or VEGF
after cerebral ischemia reduce infarct volume and ameliorate
neurological deficits [40,41,42]. High levels of GDNF, BDNF and
VEGF were found in transplanted HMO6 cells in ischemic lesion
site and responsible for restration of behavior and neuroprotec-
tion. BMP-7, a trophic factor expressed by HMO6 cells, is a
member of transforming growth factor-b superfamily, the
receptors are found in neuron and astrocytes [43] and known to
promote neuroregenerative effect in stroke rats [44]. Since BMP7
was highly expressed in HMO6 cells in penumbra, it is one of the
neuroprotective factors secreted by the transplanted HMO6
human microglial cells in the ischemic brain.
Previous studies have demonstrated that the brain transplanta-
tion of human neural stem cells overexpressing VEGF or GDNF
in cerebral hemorrhage stroke animal models promoted functional
recovery and neuronal protection [45,46]. The transplantation of
bone marrow stromal cells also promoted expression of VEGF in
host brain, and enhance angiogenesis and functional repair in the
ischemia brain [47]. The present study showed that the
transplantation of HMO6 cells in the ischemic brain induced a
significant up-regulation in expression of GDNF and VEGF in
Figure 5. Gene expression in HMO6 cell in vitro and in vivo. Gene
expression of neurotrophic factors, cytokines and chemokines in the
HMO6 cell of culture (open bars) and brain tissue (solid bars) was
analyzed by quantitative real-time PCR. Glyceraldehyde-3- phosphate
dehydrogenase (GAPDH) was used as a reaction standard. Gene
expression was determined in culture HMO6 cells under normal
condition. HMO6 cells of brain tissue were isolated from infarct core
and penumbra at 5 days after MCAO by laser capture microdissection
(LCM). Values represent mean 6 SEM from three experiments.
doi:10.1371/journal.pone.0011746.g005
Figure 6. Gene expression in rat glial cells. Gene expression of
neurotrophic factors, cytokines and chemokines in rat ED1-positive
microglia/macrophages (A) and GFAP-positive astrocytes (B) was
analyzed by quantitative real-time PCR. ED1- and GFAP-positive cells
were isolated from penumbra of the HMO6 transplantation and control
groups at 5 days after MCAO by laser capture microdissection.
Glyceraldehyde-3- phosphate dehydrogenase (GAPDH) was used as a
reaction standard. Expressional levels of each factor were calculated in
the transplantation and control groups. Values represent mean 6 SEM
from three experiments. **P,0.01 compared to the control group.
doi:10.1371/journal.pone.0011746.g006
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brain might be one of cause for neuronal recovery because those
factors can support neuronal survival and attenuate neuronal
apoptotic death [48,49].
In conclusion, the present study demonstrated that the
intravenously transplanted human microglia migrate to ischemic
area, and provide neuroprotection via producing neurotrophic
factors and cytokines and reducing endogenous glial response.
Selective accumulation of transplanted microglia in lesion core
and penumbral area indicate that that microglia could be an
effective vehicle for transfer of therapeutic genes for gene therapy
in neurological diseases including cerebral ischemic disease.
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